Frequently asked questions
Is Nitta Gelatin India a buy at current prices?
DalalBytes rates Nitta Gelatin India Selective Positive at 68/100: a 50-year Indo-Japanese JV with pharma-grade gelatin credentials (EDQM-certified, sole domestic supplier for blood plasma expander gelatin), ROCE of 27.8%, zero debt, and promoter holding of 74.5% with no pledging ever. The caution: operating margins at 20-24% sit well above CRISIL's long-term 12-15% expectation, so the stock at Rs 1,668 is priced for sustained peak margins. Own selectively and size for the cycle.
What are Nitta Gelatin India's FY2029 price targets?
DalalBytes' FY2029 targets for Nitta Gelatin India are bear Rs 670, base Rs 1,750, and bull Rs 2,600, from a Rs 1,668.40 reference price. Bear: 8% revenue CAGR, 14% OPM, 11x exit (cyclical trough). Base: 10.8% CAGR, 18% OPM, 16x exit. Bull: 17.4% CAGR, 21% OPM, 18x exit on the collagen peptide ramp. The base case is only about 5% above the reference price; the upside lives in the bull case.
What is the verdict on Nitta Gelatin India?
Nitta Gelatin India is a 50-year-old Indo-Japanese joint venture that turned crushed animal bones into one of India's highest-quality gelatin franchises: the country's sole domestic supplier of blood plasma expander gelatin, an EDQM-certified pharma-grade producer, and now a fast-scaling collagen peptide maker whose new plant was inaugurated in August 2025. The numbers read like a compounder: ROCE 27.8% in FY26, ROE above 20% for five straight years, effectively zero debt, promoter holding of 74.5% with zero pledging ever, and a clean dividend record. At a TTM P/E of about 14.4, it is the cheapest legitimate way to own this niche.
The "Selective" is doing real work. Operating margins have run at 20-24% for three straight years, and CRISIL's own long-term expectation is 12-15%: the FY24-26 record profitability was partly driven by unusually low bone prices in H1FY24, a windfall that reverses. Half of revenue is exported, the Kathikudam plant faces recurring environmental protests, and the company is mid-way through the largest capex cycle in its history. At Rs 1,668, about 20% below the 52-week high, the stock is priced for sustained peak margins. This is a quality cyclical, not a compounder on autopilot: own it selectively, size it for the cycle, and watch the bone.
How did Nitta Gelatin India start?
Incorporated on April 30, 1975 as Kerala Chemicals & Proteins Ltd, a joint venture between Kerala's KSIDC and two Japanese companies (Nitta Gelatin Inc of Osaka and Mitsubishi Corporation), it was one of India's first Indo-Japanese JVs. Commercial production began in 1979 with ossein and di-calcium phosphate from crushed animal bones; gelatin production followed in 1999 at Kakkanad, Kochi. The company was renamed Nitta Gelatin India Ltd in August 2008 and celebrated its golden jubilee in August 2025. The portfolio ladder over fifty years, from ossein for the Japanese parent to technical gelatin to pharma-grade gelatin to collagen peptides, moved the company steadily up the value chain.
What does Nitta Gelatin India make, and where does it sell?
FY24 sales mix: gelatin 59%, DCP 18%, ossein 13%, collagen peptide 9%. Pharma-grade gelatin (capsule shells) carries the real credentials: EDQM Certificate of Suitability, a Kerala Drugs Controller manufacturing license, and the sole-domestic-supplier position in blood plasma expander gelatin. Collagen peptide (Wellnex brand, launched 2009) is the growth engine; capacity nearly doubled with the June 2025 plant commissioning. About 50% of output is exported to 30-plus countries including Japan, the USA, Canada, South Korea, and Europe, with a significant share moving through the parent NGI Japan channel. Plants sit at Kathikudam (Thrissur), Kakkanad (Kochi), Reva, and Ankleshwar; the Bamni Proteins subsidiary was shut in 2024.
What do Nitta Gelatin India's financials show?
Revenue compounded at only about 5% from FY22 (Rs 506 cr) to FY26 (Rs 588 cr) while PAT compounded at roughly 31% (Rs 33 cr to Rs 97 cr): this is a margin story, not a volume story. Operating margins expanded from 12.7% (FY22 trough) to 20-24% (FY23-26), debt was eliminated to D/E 0.01, and Q1 FY27 delivered Rs 141 cr sales (+4.9% YoY) and Rs 25.2 cr PAT (+31% YoY). The critical read: the FY24 record was partly a bone-price windfall, and CRISIL's long-term OPM expectation is 12-15%. The earnings base is priced off peak margins.
How clean is the balance sheet and the promoter structure?
Net-debt-free with total debt of only about Rs 4.2 cr against Rs 511 cr net worth, operating cash flow of Rs 122.5 cr against Rs 97 cr PAT in FY26 (1.26x), and a clean dividend record (Rs 7/share for FY26). Promoter holding is 74.5%, rock-stable across quarters: Nitta Gelatin Inc (Japan) 42.96% and KSIDC 31.53%, with 0.00% pledging in every reported quarter and no dilution in five years. The company is mid-way through its largest-ever capex cycle (Rs 155-250 cr), funded by internal accruals; a proposed Rs 40 cr rights issue was withdrawn in August 2023 in a genuine capital-discipline signal.
Who does Nitta Gelatin India compete with?
Listed gelatin peers are genuinely scarce. The single domestic listed peer is India Gelatine & Chemicals (BSE: 531253): mcap about Rs 262 cr, TTM P/E about 10x, PAT Rs 26.1 cr. Global majors (Gelita, Rousselot) are unlisted. Competitive pressure comes from Chinese and other imported gelatin on price, and from the parent itself as both partner and channel. Nitta trades at roughly 1.4x its direct peer's multiple with roughly 3.3x the revenue and materially higher returns, plus the Japanese technology tie-up. Its moat is real but narrow: pharma-grade qualification barriers (EDQM, drug license, multi-year customer qualification) keep commodity competition out of the best grades, while industrial gelatin and DCP remain commodities.
What are the key risks for Nitta Gelatin India?
Margin cyclicality is the central risk: OPM at 20-24% against CRISIL's 12-15% long-term band, with the FY24 record partly a bone-price windfall. Crushed-bone prices and a 50% export share swing the P&L with commodity and currency cycles. Recurring environmental protests at Kathikudam (Thrissur) despite Rs 20 cr-plus environment capex are an unpriced disruption risk. Concentration: gelatin is 59% of sales and a significant share moves through the parent channel. Tiny free float (25.5%), about 1% institutional ownership, and low volumes make the stock highly volatile. The Rs 155-250 cr capex program is the largest in company history and is mid-execution.
© 2026 DalalBytes Research · For educational purposes only. Not investment advice.